Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1999 May;44(5):698-703.
doi: 10.1136/gut.44.5.698.

Cost comparison of predictive genetic testing versus conventional clinical screening for familial adenomatous polyposis

Affiliations
Comparative Study

Cost comparison of predictive genetic testing versus conventional clinical screening for familial adenomatous polyposis

B Bapat et al. Gut. 1999 May.

Abstract

Background: Mutations of the APC gene cause familial adenomatous polyposis (FAP), a hereditary colorectal cancer predisposition syndrome.

Aims: To conduct a cost comparison analysis of predictive genetic testing versus conventional clinical screening for individuals at risk of inheriting FAP, using the perspective of a third party payer.

Methods: All direct health care costs for both screening strategies were measured according to time and motion, and the expected costs evaluated using a decision analysis model.

Results: The baseline analysis predicted that screening a prototype FAP family would cost $4975/ pound3109 by molecular testing and $8031/ pound5019 by clinical screening strategy, when family members were monitored with the same frequency of clinical surveillance (every two to three years). Sensitivity analyses revealed that the genetic testing approach is cost saving for key variables including the kindred size, the age of screening onset, and the cost of mutation identification in a proband. However, if the APC mutation carriers were monitored at an increased (annual) frequency, the cost of the genetic screening strategy increased to $7483/ pound4677 and was especially sensitive to variability in age of onset of screening, family size, and cost of genetic testing of at risk relatives.

Conclusions: In FAP kindreds, a predictive genetic testing strategy costs less than conventional clinical screening, provided that the frequency of surveillance is identical using either strategy. An additional significant benefit is the elimination of unnecessary colonic examinations for those family members found to be non-carriers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Decision model used in the cost comparison analysis of predictive genetic versus clinical screening strategy. The two options, genetic versus clinical screening, are indicated by the shaded square on the left. Each shaded circle represents chance events; rectangles on the extreme right represent outcomes corresponding to that path in the decision tree; *complementary probability.

Similar articles

Cited by

References

    1. Proc R Soc Med. 1974 Jun;67(6 Pt 1):451-7 - PubMed
    1. Dis Colon Rectum. 1996 Apr;39(4):384-7 - PubMed
    1. Ann Intern Med. 1987 Feb;106(2):275-91 - PubMed
    1. J Med Genet. 1991 May;28(5):289-96 - PubMed
    1. Cell. 1991 Aug 9;66(3):589-600 - PubMed

Publication types